search for
or search by
PROTEIN THERAPEUTICS MARKET - Technology Advances Spur Market Growth of Protein Therapies
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
ACS MARKET - Acute Coronary Syndrome Market 2015-2025
Michela J. McMullan, PhD, GlobalData Analyst, reports that although the ACS market is set to grow at a CAGR of 4.6%, reaching $12.1B by 2025, the potential for the market to be even more lucrative exists, especially in the sizable lipid-targeting arena.
DNA SEQUENCING MARKET - Emerging Technologies & Applications
Laurie L. Sullivan and John Bergin, MS, MBA, BCC Research Analysts, indicate that NGS has matured into an essential life science tool for genetic studies in a range of applications, and the industry is on the cusp of a second growth phase, powered by new applications in clinical diagnostics.
EXECUTIVE INTERVIEW - Insulet Corporation: Improving Adherence Through Wearable, Patient-Centric Drug Delivery
Michael Graffeo, Vice President of Business Development, Insulet Delivery Systems Group, discusses the importance of optimizing patient adherence to ensure improved clinical outcomes.
John A. Bermingham, asks if you have ever been really hungry? He doesn’t mean the hunger you experience in the morning or just before dinner. He’s talking about major league hunger!
HCV MARKET - Recent Success in HCV Treatment Brings Relief to Patients but Challenges to Companies
Mirco Junker, PhD, GlobalData Analyst, says high cure rates exceeding 90% are now achievable for most patients suffering from chronic hepatitis C, and as a result, the industry is reaching a new phase in the fight against this deadly infectious disease.
NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025
Cai Xuan, PhD, and Volkan Gunduz, PhD, GlobalData Analysts, estimate that by the end of the forecast period in 2025, NSCLC sales will rise to $26.8B in the 8MM, at a moderate CAGR of 15.7%.
PLATFORM TECHNOLOGY - ​​The 3DNA® Platform for Targeted Drug Delivery
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
Avomeen Recapitalizes to Achieve Next Growth Plan Objective
In an effort to foster growth and reinforce its infrastructure, Avomeen Analytical Services, a fast growing full-service independent analytical and chemical testing laboratory based in Ann Arbor, MI, recently announced a recapitalization with High Street Capital, a Chicago-based provider of flexible capital and operating expertise to middle market businesses.
Business Development Manager Needed at Fareva
Fareva is looking for a Business Development Manager/Director for the Northern American market, based in NJ, NYC, and CT, to manage its injectables/ophthalmics/high potent businesses. The candidate should have at least 7 years of experience in technical sales in the pharmaceutical industry. Please visit and contact Ed Saxman for further information at ESaxman@ho
Cancer Vaccines Market Will Soar to $7.5 Billion by 2022
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing a strong compound annual growth rate of 16.93%, according to business intelligence provider GBI Research.
Cartridge Filling: Combination Features That Can Help Gain a Competitive Edge
By 2050, it is projected that the proportion of people aged 65 and older will be more than double that of children aged 5. This global phenomenon is also leading to an increasing number of people suffering from chronic diseases, such as diabetes and osteoporosis.
Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI).
Catalent Biologics Collaborates With PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine R&D
Catalent Pharma Solutions recently announced it has signed an agreement with PATH, an international non-profit organization and a leader in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).
Catalent to Develop Softgel Capsules for JOT's Leading Orphan Disease Candidates
Catalent Pharma Solutions recently announced that it is to evaluate Jupiter Orphan Therapeutics, Inc.’s (JOT) novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology.
Celyad's CAR-T Candidate Delivers in Early Stage Study
Celyad recently announced that first data analysis of the NKR-2 Phase I trial shows encouraging results. The NKR-2 Phase I trial is a single infusion, dose escalation study evaluating the safety and feasibility of NKR-2 T-cells in Acute Myeloid Leukemia and Multiple Myeloma patients.
Dalton Enters Into Agreement With USAMMDA in Support of US Army’s Drug Development Program
Dalton Pharma Services, a privately owned pharmaceutical services provider, recently announced that it has entered into a contract service agreement with the United States Army Medical Materiel Development Activity (USAMMDA) in support of the US Army’s product development program for the treatment of severe or complicated malaria due to Plasmodium falciparum.
Evonik Ramps Up Production Capacity for Biomaterials
Evonik is expanding its production facilities to create additional capacity for the production of biodegradable polymers marketed globally under the brand names RESOMER® and RESOMER® SELECT.
Gerresheimer Introduces Metal-Free Syringe
Biopharmaceuticals demonstrate a series of special features. They are often highly viscous and in individual cases tend to interact with silicone oil or, for example, tungsten residue from syringe production..........
Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline
Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, says business intelligence provider GBI Research.
Leading Developer of Multi-Layer Oral Thin Film Completes Going Public Transaction
CURE Pharmaceutical, a pre-eminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, recently announced the completion of a going public transaction and the issuance of its new stock symbol - CURR.
Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals
Ligand Pharmaceuticals Incorporated recently announced that partners Spectrum Pharmaceuticals (EVOMELA) and Lundbeck (CARNEVIX) received US FDA Approval.
Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma & Consumer Healthcare Industries
Lonza Group AG, KKR, and Capsugel S.A. recently announced they have entered into a definitive agreement under which Lonza will acquire Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion, through a transaction that has been approved by the Boards of Directors of both Lonza and Capsugel.
Metrics: Stability Storage Facility Q&A
Metrics Contract Services recently announced it is investing $3.5 million to build a dedicated, 15,000-square-foot stability storage facility that will triple the organization’s current storage capacity. In a Q & A, Executive Vice President John S. Ross discusses the new facility and what it means to the organization.
MilliporeSigma Launches Next-Generation Technology for Advanced Live Cell Imaging
MilliporeSigma has launched the CellASIC® ONIX2 Microfluidic System for advanced live cell imaging. The system converts laboratory microscopes into powerful tools for live cell imaging to more effectively perform in-depth analysis of cellular mechanisms and behavior in a live environment.
Nemus Bioscience Announces Licensing Agreement for a Cannabinoid-Based Anti-Infective Platform Directed Against Drug-Resistant Organisms
NEMUS Bioscience, Inc. (NMUS) announced that the company had signed a licensing agreement with the University of Mississippi (UM) for a platform of cannabinoid-based molecules (UM5070) for potential anti-infective use against bacteria, viruses, and fungi.
PCI Clinical Services & Suvoda Announce Strategic Partnership
PCI Clinical Services recently announced a partnership with Suvoda LLC that will benefit clinical trials, delivering Suvoda’s cutting-edge IRT/IWRS technology for subject randomization and trial supply management integrated with PCI’s comprehensive packaging and logistical services for clinical trial supplies.
Positive Results for Alkermes' Phase III Study Spell Good News for Major Depressive Disorder Space
Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according to research and consulting firm GlobalData.
Progenics Announces $50-Million Infusion to Advance Portfolio
Progenics Pharmaceuticals, Inc. recently announced its wholly owned subsidiary MNTX Royalties Sub LLC has entered into a $50-million term loan agreement with a fund managed by HealthCare Royalty Partners (HCR) secured by, and to be repaid from, royalties from future sales of RELISTOR.
Vetter: Choosing the Right Diluent to Help Maximize Success
The biologics market continues to rise, expecting to reach $250 billion by 2024. Due to the unstable nature and limited shelf life of many biopharmaceutical compounds, there is an increase in the demand for lyophilized drugs.
Vetter's Skokie Site Successfully Manufactures Batches on New Clinical Syringe Filling Line
Vetter, a leading international contract development and manufacturing organization (CDMO) that specializes in aseptic filling for its (bio-)pharmaceutical customers, recently announced that its new clinical syringe line has already manufactured for its customers a double digit number of batches for use in early clinical trials.
West Announces Expanded Contract Manufacturing Capabilities in Ireland
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced the completion of a 60,000 square foot expansion at its contract manufacturing facility near Mulhuddart, County Dublin.


Click here to see the showcases

Drug Delivery Partnerships Meeting
February 7-9
Palm Beach Gardens, FL

March 21-23
New York, NY

PDA Annual Meeting
April 3-5
Anaheim, CA

RDD (Respiratory Drug Delivery)
April 25-28
Nice, France

AAPS National Biotechnology Meeting
May 1-3
San Diego, CA

Innovation Networking Summit & Table-top Exhibition
May 4-5
Hilton Hotel, Parsippany, NJ

CPhI North America & Informex
May 16-18
2017 Philadelphia, PA

BIO 2017
June 19 - 22
San Diego, CA

Controlled Release Society Meeting
July 16-19 Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Nienna, Austria

November 12-17
San Diego, CA


Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions